Alphyn…announced today that the U.S. Patent and Trademark Ofﬁce (USPTO) has granted a patent for the active pharmaceutical ingredient (API) in its lead candidate for atopic dermatitis (AD)

zabalafin hydrogel (AB-101a) - Alphyn Biologics

Oct 27, 2025